Mark C. McKenna - 11 Aug 2025 Form 4 Insider Report for BridgeBio Oncology Therapeutics, Inc. (HLXB)

Reporting relationship: Former Director
Issuer ticker: HLXB
Reported as of: 11 Aug 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Aug 2025, 17:01:51 UTC
Prior SEC filing: 20 Jun 2025
Next SEC filing: 09 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Mark C. McKenna

Key filing fact

Mark C. McKenna filed Form 4 for BridgeBio Oncology Therapeutics, Inc. (HLXB) on 11 Aug 2025.

Key facts

This page summarizes Mark C. McKenna's Form 4 filing for BridgeBio Oncology Therapeutics, Inc. (HLXB).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 11 Aug 2025, 17:01.

Change

Previous filing in this sequence was filed on 20 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001749623 Primary reporting owner

McKenna Mark C.

Relationship: Former Director
Address: C/O HELIX ACQUISITION CORP. II, 200 CLARENDON STREET, 52ND FLOOR, BOSTON
Signature: /s/ Mark C. McKenna
Signature date: 11 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BBOT transaction

Common Stock

Options Exercise

Transaction value
Shares: +30,000
Change %
Price
Shares after: 30,000
Date: 11 Aug 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BBOT transaction Derivative

Class B ordinary shares

Options Exercise

Transaction value: $0
Shares: -30,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 11 Aug 2025
Ownership: Direct
Underlying class: Class A ordinary shares
Underlying amount: 30,000
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Mark C. McKenna is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

In connection with and prior to the closing of the business combination between the Issuer (which was formerly known as Helix Acquisition Corp. II, "Helix") and TheRas, Inc., among other things, (i) each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, on a one-for-one basis, as described under the heading "Description of Securities" in Helix's Registration Statement on Form S-1 (File No. 333-276591), (ii) Helix migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended, and the Cayman Islands Companies Act (As Revised) (the "Domestication"), and (iii) as a result of the Domestication, each Class A ordinary share of Helix converted into one share of the Issuer's common stock, on a one-for-one basis. Prior to such conversion, the Helix Class B ordinary shares had no expiration date.

SEC remarks

The Reporting person was a director of Helix prior to the Domestication and resigned from such role effective as of August 11, 2025, immediately prior to the Domestication.